CAM
IDIX

Capstone Asset Management’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Capstone Asset Management’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,462
Closed -$54K – 2037
2013
Q3 		$54K Sell
10,462
-50
-0.5% -$219 ﹤0.01% 1982
2013
Q2 		$38K Buy
+10,512
New +$43K ﹤0.01% 1948

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Capstone Asset Management's IDIX Position: Q4 2013 in Review

Capstone Asset Management sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q4 2013, closing a stake of 10,462 shares — an estimated $54K sold.

Capstone Asset Management first reported a position in IDIX in Q2 2013 and held it in 2 quarters. The position peaked at $54K in Q3 2013. 88 funds tracked by Wall St. Rank hold IDIX as of Q4 2013.

  • Capstone Asset Management reported no remaining IDENIX PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Capstone Asset Management sold 10,462 IDENIX PHARMACEUTICALS INC shares in Q4 2013, an estimated $54K.
  • Capstone Asset Management first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Capstone Asset Management's IDENIX PHARMACEUTICALS INC position peaked at $54K in Q3 2013.
  • 88 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q4 2013.

Based on Capstone Asset Management's 13F filing for Q4 2013, filed 4 Feb 2014.